Translational Research

Translational Research

Translational research transforms scientific discoveries arising from fundamental studies into clinical applications to improve outcomes for patients with prostate cancer. Members of this team work together to employ innovative new technologies for biomarker discovery, detection and quantification that have been developed independently in internationally-recognized efforts in Alberta and bring them to bear on a common goal – developing better tests for prostate cancer.

The combination of prognostic biomarkers from distinct aspects of prostate cancer progression resulted in a test that is more sensitive, more accurate and more cost effective than current tests for prostate cancer.

Our overall goal is to improve patient outcomes and quality of life by translating novel tests to the clinic that are more sensitive, more accurate and more cost-effective than current tests for prostate cancer. No one dies from prostate cancer that is localized to the prostate – the spread, or metastasis, of prostate cancer is what makes it so dangerous. The five year survival rate for localized prostate cancer in North America is close to 100%, yet this drops to 30% for metastatic disease. The metastasis of prostate cancer is driven primarily by changes in growth factors, extracellular proteases, and the cell migration machinery. Biomarkers that are involved in these processes are prognostic for metastatic prostate cancer and their integration into a single powerful test are the focus of this multi-disciplinary team.

Our team is integrating internationally-recognized efforts in the characterization of tumour cell migration, growth factor signaling and protease-activated receptors to develop novel multiplex tests to more accurately predict outcomes in prostate cancer.

translational-research-image

APCaRI is part of the Movember Prostate Cancer Outcomes network

The Prostate Cancer Outcomes Global Initiative to Compare and Reduce Variation is a project led by Movember aiming to improve health outcomes for men throughout their prostate cancer journey by focusing on variation in care and engaging clinicians and researchers across 14 countries worldwide.

The international team will collect data from prostate cancer patients segmented into the categories of data items as outlined by the International Consortium for Health Outcomes Measurement (ICHOM). These include patient factors, baseline tumor factors, pathological information, treatment variables, acute complications of treatment, and survival and disease control).

The Alberta Prostate Cancer dataset is highly aligned with the ICHOM standards. This means that we can effectively compare treatments and outcomes in Alberta with teams around the world to find ways to improve our care at home and abroad!

This is the result of hours of planning and true team work lead by Dr. Trafford Crump, the APCaRI Scientific and Data Quality Committee, and the APCaRI clinical, scientific, research and pathology teams. Thanks to your efforts, we are one step closer to improving patient outcomes.

- John Lewis